Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday

Allakos (NASDAQ:ALLK) is projected to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Allakos Trading Up 0.9 %

Allakos stock opened at $0.26 on Thursday. The company has a market capitalization of $23.32 million, a PE ratio of -0.13 and a beta of 0.72. Allakos has a 12 month low of $0.23 and a 12 month high of $1.56. The stock has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.81.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ALLK. Citizens Jmp cut Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Piper Sandler cut Allakos from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 27th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $2.00.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.